Clinical Trials Browser

Phase 1 × Liposarcoma, Myxoid × pembrolizumab × Clear all

NCT05492682 2025-09-05

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

BreastDermatologicGastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms